[Chemotherapy for advanced gastric cancer--our possibilities in 2007].
Gastric cancer is the fourth most common malignancy in Hungary. Surgery remains the mainstay of any curative treatment, however, approximately two-thirds of patients diagnosed with gastric cancer have unresectable (locally advanced and/or metastatic) disease. In that stage, palliative chemotherapy is of crucial importance. Gastric cancer is heterogeneous regarding location, etiology, histology and natural course. This diversity is reflected in the results of randomized controlled trials as well. Patient selection, location of primary, stage and pretreatment of the tumor, as well as the reference treatment, patient stratification and endpoints have varied among trials. Based on the results of the clinical trials of the past decades, gastric cancer is chemosensitive, however, patient prognosis remains very poor, with a median survival of less than one year, and therapy-associated toxicity remains an issue. Based on the aforementioned, no standard regimens have yet been established worldwide. New compounds and targeted biological treatment make the development of more effective, less toxic, individualized treatment modalities possible.
Dank
Magdolna
M
Radiológiai és Onkoterápiás Klinika, Semmelweis Egyetem, Budapest, Hungary. dank@radi.sote.hu
Torgyík
László
L
Szentmártoni
Gyöngyvér
G
D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D006801:Humans; D006814:Hungary / Q000453:epidemiology; D015994:Incidence; D009367:Neoplasm Staging; D010166:Palliative Care / Q000379:methods; D011379:Prognosis; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000453:epidemiology / Q000473:pathology
D000970:Antineoplastic Agents